Close Menu

NEW YORK – Castle Biosciences said after the close of the market on Tuesday that it has priced an underwritten public offering of 4 million shares of its common stock at $58 per share.

The company expects $232 million in gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses. In addition, Castle has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the offering price. The offering is expected to close on or about December 18.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.